FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2029794295> ?p ?o ?g. }

• W2029794295 endingPage "1187" @default.
• W2029794295 startingPage "1181" @default.
• W2029794295 abstract "Serious bacterial infections are common in children infected with the human immunodeficiency virus (HIV). Studies performed before zidovudine became standard therapy found that intravenous immune globulin decreases the number of serious bacterial infections in these children. We designed a multicenter study to evaluate the efficacy of intravenous immune globulin in children with advanced HIV infection who were receiving zidovudine.In a double-blind trial 255 children between 3 months and 12 years of age who had the acquired immunodeficiency syndrome (AIDS) or AIDS-related complex were randomly assigned to receive either intravenous immune globulin (400 mg per kilogram of body weight) (n = 129) or placebo (0.1 percent albumin) (n = 126) every 28 days. All children received 180 mg of zidovudine per square meter of body-surface area orally four times daily. Treatment assignment was stratified according to whether the patients had a history of one or more serious bacterial infections, had previously been treated with zidovudine, or were currently receiving prophylaxis with trimethoprim-sulfamethoxazole. The median length of follow-up was 30.6 months.The estimated two-year rates of serious bacterial infections with confirmed pathogens were 16.9 percent for the immune globulin group and 24.3 percent for the placebo group (relative risk, 0.60; 95 percent confidence interval, 0.35 to 1.04; P = 0.07). The treatment effect was seen primarily among the 174 children who were not receiving trimethoprim-sulfamethoxazole prophylaxis at entry; the estimated two-year rates of infection were 11.3 percent for the immune globulin group and 26.8 percent for the placebo group (relative risk, 0.45; 95 percent confidence interval, 0.22 to 0.91; P = 0.03). For the 81 children who were receiving trimethoprim-sulfamethoxazole prophylaxis initially, the rates were 27.7 percent in the immune globulin group and 17.7 percent in the placebo group (relative risk, 1.26; 95 percent confidence interval, 0.44 to 3.66; P = 0.67). The two-year survival was similar in the two groups: 79.2 percent among immune globulin recipients and 75.4 percent among placebo recipients (P = 0.41).In children with advanced HIV disease who are receiving zidovudine, intravenous immune globulin decreases the risk of serious bacterial infections. However, this benefit is apparent only in children who are not receiving trimethoprim-sulfamethoxazole as prophylaxis." @default.
• W2029794295 created "2016-06-24" @default.
• W2029794295 creator A5008280183 @default.
• W2029794295 creator A5017306542 @default.
• W2029794295 creator A5040290360 @default.
• W2029794295 creator A5058296985 @default.
• W2029794295 creator A5058881734 @default.
• W2029794295 creator A5064225735 @default.
• W2029794295 creator A5069688312 @default.
• W2029794295 creator A5072253318 @default.
• W2029794295 creator A5089821583 @default.
• W2029794295 creator A5091093164 @default.
• W2029794295 date "1994-11-03" @default.
• W2029794295 modified "2023-09-24" @default.
• W2029794295 title "A Controlled Trial of Intravenous Immune Globulin for the Prevention of Serious Bacterial Infections in Children Receiving Zidovudine for Advanced Human Immunodeficiency Virus Infection" @default.
• W2029794295 cites W1991883424 @default.
• W2029794295 cites W1996414664 @default.
• W2029794295 cites W2005526186 @default.
• W2029794295 cites W2027644619 @default.
• W2029794295 cites W2042391678 @default.
• W2029794295 cites W2059707463 @default.
• W2029794295 cites W2083117411 @default.
• W2029794295 cites W2083626957 @default.
• W2029794295 cites W2111704944 @default.
• W2029794295 cites W2117897510 @default.
• W2029794295 cites W2317811229 @default.
• W2029794295 cites W2773826105 @default.
• W2029794295 cites W3020963154 @default.
• W2029794295 cites W3027534291 @default.
• W2029794295 cites W3041047318 @default.
• W2029794295 cites W4234719625 @default.
• W2029794295 doi "https://doi.org/10.1056/nejm199411033311802" @default.
• W2029794295 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7935655" @default.
• W2029794295 hasPublicationYear "1994" @default.
• W2029794295 type Work @default.
• W2029794295 sameAs 2029794295 @default.
• W2029794295 citedByCount "131" @default.
• W2029794295 countsByYear W20297942952012 @default.
• W2029794295 countsByYear W20297942952013 @default.
• W2029794295 countsByYear W20297942952014 @default.
• W2029794295 countsByYear W20297942952015 @default.
• W2029794295 countsByYear W20297942952016 @default.
• W2029794295 countsByYear W20297942952017 @default.
• W2029794295 countsByYear W20297942952018 @default.
• W2029794295 countsByYear W20297942952021 @default.
• W2029794295 countsByYear W20297942952022 @default.
• W2029794295 countsByYear W20297942952023 @default.
• W2029794295 crossrefType "journal-article" @default.
• W2029794295 hasAuthorship W2029794295A5008280183 @default.
• W2029794295 hasAuthorship W2029794295A5017306542 @default.
• W2029794295 hasAuthorship W2029794295A5040290360 @default.
• W2029794295 hasAuthorship W2029794295A5058296985 @default.
• W2029794295 hasAuthorship W2029794295A5058881734 @default.
• W2029794295 hasAuthorship W2029794295A5064225735 @default.
• W2029794295 hasAuthorship W2029794295A5069688312 @default.
• W2029794295 hasAuthorship W2029794295A5072253318 @default.
• W2029794295 hasAuthorship W2029794295A5089821583 @default.
• W2029794295 hasAuthorship W2029794295A5091093164 @default.
• W2029794295 hasBestOaLocation W20297942951 @default.
• W2029794295 hasConcept C126322002 @default.
• W2029794295 hasConcept C142724271 @default.
• W2029794295 hasConcept C203014093 @default.
• W2029794295 hasConcept C204787440 @default.
• W2029794295 hasConcept C27081682 @default.
• W2029794295 hasConcept C2779425571 @default.
• W2029794295 hasConcept C2780216070 @default.
• W2029794295 hasConcept C2780727368 @default.
• W2029794295 hasConcept C2780728791 @default.
• W2029794295 hasConcept C3013748606 @default.
• W2029794295 hasConcept C501593827 @default.
• W2029794295 hasConcept C71924100 @default.
• W2029794295 hasConcept C86803240 @default.
• W2029794295 hasConcept C89423630 @default.
• W2029794295 hasConceptScore W2029794295C126322002 @default.
• W2029794295 hasConceptScore W2029794295C142724271 @default.
• W2029794295 hasConceptScore W2029794295C203014093 @default.
• W2029794295 hasConceptScore W2029794295C204787440 @default.
• W2029794295 hasConceptScore W2029794295C27081682 @default.
• W2029794295 hasConceptScore W2029794295C2779425571 @default.
• W2029794295 hasConceptScore W2029794295C2780216070 @default.
• W2029794295 hasConceptScore W2029794295C2780727368 @default.
• W2029794295 hasConceptScore W2029794295C2780728791 @default.
• W2029794295 hasConceptScore W2029794295C3013748606 @default.
• W2029794295 hasConceptScore W2029794295C501593827 @default.
• W2029794295 hasConceptScore W2029794295C71924100 @default.
• W2029794295 hasConceptScore W2029794295C86803240 @default.
• W2029794295 hasConceptScore W2029794295C89423630 @default.
• W2029794295 hasIssue "18" @default.
• W2029794295 hasLocation W20297942951 @default.
• W2029794295 hasLocation W20297942952 @default.
• W2029794295 hasLocation W20297942953 @default.
• W2029794295 hasOpenAccess W2029794295 @default.
• W2029794295 hasPrimaryLocation W20297942951 @default.
• W2029794295 hasRelatedWork W1948531513 @default.
• W2029794295 hasRelatedWork W1965333153 @default.
• W2029794295 hasRelatedWork W2016793986 @default.
• W2029794295 hasRelatedWork W2061701520 @default.
• W2029794295 hasRelatedWork W2517207989 @default.

• next